Good morning :)
$
₹
Erasca Inc

Erasca Inc

ERAS

NASDAQ
Asset Logo

Erasca Inc

ERAS

NASDAQ
$14.408.58% (+1.13)
$
₹
$14.408.58% (+1.13)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $5.2B the stock is ranked 1435

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

14.16
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.95
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 9 analysts reports

Buy
7 analysts
Hold
2 analysts
Sell
0 analyst

Price Upside

+67.32%

Earnings Growth

-121.86%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.65
50.65
1Y Return
31.59%
31.59%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.73
27.73
1Y Return
46.88%
46.88%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
35.24%
35.24%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.33
35.33
1Y Return
31.43%
31.43%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
944.75%
944.75%
Buy Reco %
17.39
17.39
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 67.32% growth, versus a trailing 3-year CAGR of 82.26%.

2026
Current$14.41Baseline
Analyst Target - 1 year
Target$24.11+67.32%

All values in $

202220232024202520262027$8.07$14.22$20.37Target+67.32%
2026
Current$14.41Baseline
Analyst Target - 1 year
Target$24.11+67.32%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-0.44Baseline
Forecast for Dec 2026
High$-0.86-95.45%
Average$-0.98-121.86%
Low$-1.06-140.91%

All values in $

202120222023202420252026-2.67-1.96-0.83-0.74-0.44Low-140.91%Average-121.86%High-95.45%
2025
Current$-0.44Baseline
Forecast for Dec 2026
High$-0.86-95.45%
Average$-0.98-121.86%
Low$-1.06-140.91%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-30.6
-29
-183.4
-44
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0004.19000000
Net Income-35.01-63.20-31.2-32.23-30.96-33.87-30.61-29.09-183.44-44.07
Net Profit Margin----768.16%------
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Erasca Inc -14.16-
AbbVie Inc50.6550.450.58
Amgen Inc27.7321.332.75
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare ERAS with any stock or ETF
Compare ERAS with any stock or ETF
Comparing from
ERAS
ABBV
AMGN
Loading...

Frequently asked questions

  1. Erasca Inc (ERAS) share price today is $14.40 as of November 7, 2026 at 2:29 AM IST. The stock touched a day high of $14.40 and a day low of $13.13.

  2. Erasca Inc stock trades on NASDAQ under the ticker symbol ERAS.

  3. Erasca Inc's market capitalization is $5.21B as of November 7, 2026 at 2:29 AM IST.

  4. Erasca Inc's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.

  5. Erasca Inc's price-to-book (P/B) ratio is 14.16 as of November 6, 2026.

  6. Yes, You can buy Erasca Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Erasca Inc shares in three steps: 1. Search Erasca Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Erasca Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Erasca Inc (ERAS) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.694 shares at the current price of $14.40.

Loading...